ABSTRACT
Ciguatoxins are algal toxins responsible for tens of thousands of human intoxications yearly, both in tropical and subtropical endemic regions as well as worldwide through fish exportation. Previously developed methods for biotoxin surveillance in the environment and seafood include analytical methods and in vivo and in vitro bioassays. The radioligand receptor binding assay (r-RBA) is among the in vitro methodologies currently used for the detection and quantification of marine biotoxins. For the ciguatoxin group, the r-RBA has been widely used as a means to characterize the mode of action and as detection method in various biological matrices. Yet, screening methods have not been standardized, and the details of the ciguatoxin-specific r-RBA are not well-documented, which limit interlaboratory comparison and progress toward method validation. This work presents the development of an optimized r-RBA for ciguatoxins and provides guidance on its use and quality control checks for analysis of environmental samples. We focus on the analysis of critical parameters involved in determining assay acceptability. Calculation of toxin concentrations in fish samples is illustrated with four examples. Thus, this paper provides the detailed information required for a full validation of the r-RBA, a necessary step toward the development and implementation of a regulatory monitoring programme for ciguatoxins in seafood products using the r-RBA.
Subject(s)
Ciguatoxins/analysis , Environmental Monitoring/methods , Radioligand Assay/methods , Water Pollutants/analysisABSTRACT
One of the cornerstones of rational drug development is the measurement of molecular parameters derived from ligand-receptor interaction, which guides therapeutic windows definition. Over the last decades, radioligand binding has provided valuable contributions in this field as key method for such purposes. However, its limitations spurred the development of more exquisite techniques for determining such parameters. For instance, safety risks related to radioactivity waste, expensive and controlled disposal of radioisotopes, radiotracer separation-dependence for affinity analysis, and one-site mathematical models-based fitting of data make radioligand binding a suboptimal approach in providing measures of actual affinity conformations from ligands and G proteincoupled receptors (GPCR). Current advances on high-throughput screening (HTS) assays have markedly extended the options of sparing sensitive ways for monitoring ligand affinity. The advent of the novel bioluminescent donor NanoLuc luciferase (Nluc), engineered from Oplophorus gracilirostris luciferase, allowed fitting bioluminescence resonance energy transfer (BRET) for monitoring ligand binding. Such novel approach named Nluc-based BRET (NanoBRET) binding assay consists of a real-time homogeneous proximity assay that overcomes radioligand binding limitations but ensures the quality in affinity measurements. Here, we cover the main advantages of NanoBRET protocol and the undesirable drawbacks of radioligand binding as molecular methods that span pharmacological toolbox applied to Drug Discovery. Also, we provide a novel perspective for the application of NanoBRET technology in affinity assays for multiple-state binding mechanisms involving oligomerization and/or functional biased selectivity. This new angle was proposed based on specific biophysical criteria required for the real-time homogeneity assigned to the proximity NanoBRET protocol.
Subject(s)
Drug Discovery/trends , Fluorescence Resonance Energy Transfer/methods , Pharmacology/trends , Radioligand Assay , Ligands , Luciferases/metabolism , Luminescent Measurements/methods , Protein Binding , Radioisotopes/pharmacology , Radioligand Assay/methods , Receptors, G-Protein-Coupled/metabolismABSTRACT
Previous studies have shown that uliginosin B inhibits dopamine reuptake in rat brain. This compound occurs in Hypericum polyanthemum and H. caprifoliatum for which was reported to have antinociceptive effect sensitive to naloxone. The aim of this study was to assess the antinociceptive effect of uliginosin B and to evaluate the involvement of opioid and dopaminergic receptors activation. Uliginosin B presented antinociceptive effect in hot-plate and abdominal writhing tests, in mice, at doses that did not impair the motor coordination (15 mg/kg, i.p.). Uliginosin B in high dose (90 mg/kg, i.p.) presented ataxic effect in the rotarod apparatus. These effects seem to be mediated by distinct receptors since the effect on the hot-plate was completely abolished by naloxone and sulpiride, but it was unaffected by SCH 23390. On the other hand, the motor impairment induced by uliginosin B was completely prevented by naloxone and partially prevented by sulpiride and SCH 23390. However, the receptors' activation appears to be indirect since uliginosin B did not bind to opioid and dopaminergic receptors. Thus, uliginosin B effects probably are due to its ability to inhibit monoamine reuptake with consequent activation of dopamine receptors and indirect stimulation of opioid system.
Subject(s)
Analgesics/pharmacology , Phloroglucinol/analogs & derivatives , Receptors, Dopamine/metabolism , Receptors, Opioid/metabolism , Analgesics/antagonists & inhibitors , Animals , Benzazepines/pharmacology , Brain/drug effects , Brain/metabolism , Dopamine Antagonists/pharmacology , Drug Interactions , Male , Mice , Mice, Inbred Strains , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Pain Measurement/drug effects , Pain Measurement/methods , Pain Measurement/statistics & numerical data , Phloroglucinol/antagonists & inhibitors , Phloroglucinol/pharmacology , Radioligand Assay/methods , Rats , Rats, Sprague-Dawley , Rotarod Performance Test/statistics & numerical data , Sulpiride/pharmacologyABSTRACT
In this paper we demonstrate that, circulating antibodies from schizophrenic patients interacting with cerebral M1 muscarinic acetylcholine receptors (M1 mAChRs), can act as an inducer of m1 mAChR-mRNA, and neuronal nitric oxide synthase (nNOS) mRNA gene expression of rat frontal cortex. The different signaling pathways involved in the autoantibody's actions, were characterized. As previously reported serum autoantibodies from schizophrenic patients reacted against neural cells surface inhibiting the binding of the specific mAChR radioligand to rat cerebral frontal cortex membrane. Moreover, by ELISA using M1 synthetic peptide (with identical aminoacid sequence to human M1 mAChR) as coating antigen we demonstrated the reactivity against the second extracellular loop of human cerebral M1 mAChR. The corresponding affinity-purified anti M1 peptide IgG (anti M1 peptide IgG) from schizophrenic patients by stimulation of M1 mAChR exerted an increase in m1 mAChR-mRNA and nNOS-mRNA levels, that significantly correlated with the accumulation of phosphoinositides (IPs) and activation of NOS (alpha = 0.05). All these effects were blunted by pirenzepine and mimicked the action of the authentic agonist. Concurrent analysis of the effects of nNOS, phospholipase C (PLC) and calcium/calmodulin (CaM) inhibition on both, m1 mAChR-mRNA and nNOS-mRNA levels, showing that antibody up-regulation mRNA level is under the control of endogenous nitric oxide (NO) signaling system. On the basis of our results, the activation of M1 mAChR by schizophrenic autoantibody appears to induce nNOS-mRNA expression and reciprocally, the activation of NOS up-regulates m1 mAChR gene expression. These results gave support to the participation of an autoimmune process in a particular group of chronic schizophrenic patients.
Subject(s)
Autoantibodies/pharmacology , Gene Expression Regulation/drug effects , Nitric Oxide Synthase Type I/metabolism , Receptor, Muscarinic M1/metabolism , Schizophrenia/immunology , Adult , Analysis of Variance , Animals , Autoantibodies/chemistry , Blotting, Northern/methods , Cerebral Cortex/cytology , Cerebral Cortex/drug effects , Chromatography, Affinity/methods , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay/methods , Female , Gene Expression Regulation/physiology , Humans , Inositol Phosphates/metabolism , Male , Middle Aged , Muscarinic Antagonists/pharmacokinetics , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type I/genetics , Quinuclidinyl Benzilate/pharmacokinetics , Radioligand Assay/methods , Rats , Rats, Wistar , Receptor, Muscarinic M1/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods , Tritium/pharmacokineticsABSTRACT
Behavioural changes, muscarinic and dopaminergic receptors density and levels of monoamines were measured in striatum of rats after pilocarpine-induced status epilepticus (SE). Wistar rats at the age of 21 days were treated with pilocarpine (400mg/kg; subcutaneously) whilst the control group was treated with 0.9% saline (s.c.). Both groups were sacrificed 1h following the treatment. SE induced a muscarinic receptor downregulation of 64% in pilocarpine group. This effect was also observed to be 57% in D(1) and 32% in D(2). In the dissociation constant (K(d)) values in muscarinic and D(1) receptor no alterations were verified. On the other hand, the K(d) value for D(2) was observed to increase 41%. High performance liquid chromatography determinations showed 63, 35, 77 and 64% decreases in dopamine, 3-methoxy-phenylacetic acid, serotonin and 5-hydroxyindoleacetic acid contents, respectively. The homovanilic acid level was verified to increase 119%. The noradrenaline content was unaltered. A direct evidence of monoamine levels alterations can be verified during seizure activity and receptor density changes appear to occur in an accentuated way in immature brain during the estabilishment of SE induced by pilocarpine.
Subject(s)
Biogenic Monoamines/metabolism , Corpus Striatum/drug effects , Pilocarpine , Receptors, Dopamine/metabolism , Receptors, Muscarinic/metabolism , Status Epilepticus/chemically induced , Analysis of Variance , Animals , Animals, Newborn , Behavior, Animal/drug effects , Benzazepines/pharmacokinetics , Corpus Striatum/metabolism , Dopamine Antagonists/pharmacokinetics , Gene Expression Regulation/drug effects , Male , N-Methylscopolamine/pharmacokinetics , Radioligand Assay/methods , Rats , Rats, Wistar , Receptors, Dopamine/classification , Receptors, Muscarinic/classification , Status Epilepticus/metabolism , Tritium/pharmacokineticsABSTRACT
Endopeptidase 24.15 (ep24.15: EC3.4.24.15), a secreted protein involved in peptide metabolism, is unusual in that it does not contain a signal peptide sequence. In this work, we describe the physical interaction between ep24.15 and 14-3-3 epsilon, one isoform of a family of ubiquitous phosphoserine/threonine-scaffold proteins that organizes cell signaling and is involved in exocytosis. The interaction between ep24.15 and 14-3-3 epsilon increased following phosphorylation of ep24.15 at Ser(644) by protein kinase A (PKA). The co-localization of ep24.15 and 14-3-3 epsilon was increased by exposure of HEK293 cells (human embryonic kidney cells) to forskolin (10 microm). Overexpression of 14-3-3 epsilon in HEK293 cells almost doubled the secretion of ep24.15 stimulated by A23187 (7.5 microm) from 10%[1.4 +/- 0.24 AFU/(min 10(6) cells)] to 19%[2.54 +/- 0.24 AFU/(min 10(6) cells)] (p < 0.001) of the total intracellular enzyme activity. Treatment with forskolin had a synergistic effect on the A23187-stimulated secretion of ep24.15 that was totally blocked by the PKA inhibitor KT5720. The ep24.15 point mutation S644A reduced the co-localization of ep24.15 and 14-3-3 in stably transfected HEK293 cells. Indeed, secretion of the ep24.15 S644A mutant from these cells was only slightly stimulated by A23187 and insensitive to forskolin, in contrast to that of the wild type enzyme. Together, these data suggest that prior interaction with 14-3-3 is an important step in the unconventional stimulated secretion of ep24.15.
Subject(s)
14-3-3 Proteins/metabolism , Metalloendopeptidases/metabolism , 14-3-3 Proteins/physiology , Animals , Blotting, Western/methods , Brain/metabolism , Cloning, Molecular/methods , Colforsin/pharmacology , Cyclic AMP-Dependent Protein Kinases/pharmacology , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , Humans , Immunohistochemistry/methods , Immunoprecipitation/methods , Microscopy, Confocal , Mutagenesis, Site-Directed/physiology , Phosphorylation/drug effects , RNA, Messenger/biosynthesis , Radioligand Assay/methods , Rats , Recombinant Fusion Proteins , Reverse Transcriptase Polymerase Chain Reaction/methods , Secretory Rate/drug effects , Transfection/methods , Trypan Blue , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism , Two-Hybrid System TechniquesABSTRACT
Experiments were designed to reproduce the antiepileptic effects of low frequency stimulation (LFS) during the amygdala kindling process and to examine LFS-induced changes in receptor binding levels of different neurotransmitters in normal brain. Male Wistar rats were stereotactically implanted in the right amygdala with a bipolar electrode. Rats (n = 14) received twice daily LFS (15 min train of 1Hz, 0.1 ms at an intensity of 100 to 400 microA) immediately after amygdala kindling stimulation (1s train of 60 Hz biphasic square waves, each 1 ms at amplitude of 200-500 microA) during 20 days. The LFS suppressed epileptogenesis (full attainment of stage V kindling) but not the presence of partial seizures (lower stages of kindling) in 85.7% of the rats. Thereafter, normal rats (n = 7) received amygdala LFS twice daily for 40 trials. Animals were sacrificed 24 h after last stimulation and their brain used for labeling mu opioid, benzodiazepine (BZD), alpha(1)-adrenergic, and adenylyl cyclase binding. Autoradiography experiments revealed increased BZD receptor binding in basolateral amygdala (20.5%) and thalamus (29.3%) ipsilateral to the place of stimulation and in contralateral temporal cortex (18%) as well as decreased values in ipsilateral frontal cortex (24.2%). Concerning mu receptors, LFS decreased binding values in ipsilateral sensorimotor (7.2%) and temporal (5.6%) cortices, dentate gyrus (5.8% ipsi and 6.8% contralateral, respectively), and contralateral CA1 area of dorsal hippocampus (5.5%). LFS did not modify alpha(1) receptor and adenylyl cyclase binding values. These findings suggest that the antiepileptic effects of LFS may involve activation of GABA-BZD and endogenous opioid systems.
Subject(s)
Brain/metabolism , Receptors, Adrenergic, alpha-1/metabolism , Receptors, GABA-A/metabolism , Receptors, Opioid, mu/metabolism , Animals , Electric Stimulation/methods , Male , Protein Binding/physiology , Radioligand Assay/methods , Rats , Rats, WistarABSTRACT
It has been proposed that anti-myocardial antibodies (Ab) against neurotransmitter (NT) receptors are involved in the immunopathology of chronic Chagas' heart disease. We demonstrated that an anti-Trypanosoma cruzi monoclonal Ab (mAb), CAK20.12, binds to murine cardiac beta-adrenergic and muscarinic acetyl choline (mACh) receptors eliciting abnormal physiological responses on normal heart. No cross-linking requirement for mAb actions was demonstrated using Fab fragment derived from CAK20.12. mAb binding to synthetic peptides from the second extracellular loop of both beta1-adrenergic and mACh receptors, demonstrated by ELISA, identified the region of NT receptors involved. Cross-reactivity between these peptides and T. cruzi antigen was confirmed by binding inhibition assays. These results support the existence of cross-reactivity due to molecular mimicry between a parasite antigen and the major antigenic epitopes present on both beta1-adrenergic and M2-ACh receptors. Its possible relationship with cardiac dysfunction during chronic stage of Chagas' disease is also discussed.
Subject(s)
Antibodies, Monoclonal/pharmacology , Antibodies, Protozoan/pharmacology , Myocardial Contraction/drug effects , Pindolol/analogs & derivatives , Receptor, Muscarinic M2/immunology , Receptors, Adrenergic, beta-1/immunology , Trypanosoma cruzi/immunology , Adrenergic beta-Antagonists , Analysis of Variance , Animals , Binding, Competitive/drug effects , Binding, Competitive/physiology , Cyclic AMP/metabolism , Cyclic GMP/metabolism , Dose-Response Relationship, Drug , Drug Interactions , Enzyme-Linked Immunosorbent Assay/methods , Epitopes/metabolism , Epitopes/pharmacology , Immunoglobulin Fab Fragments/metabolism , In Vitro Techniques , Iodine Isotopes/pharmacokinetics , Mice , Mice, Inbred BALB C , Muscarinic Antagonists/pharmacokinetics , Myocardial Contraction/physiology , Pindolol/pharmacokinetics , Quinuclidinyl Benzilate/pharmacokinetics , Radioimmunoassay/methods , Radioligand Assay/methods , Receptor, Muscarinic M2/chemistry , Receptors, Adrenergic, beta-1/chemistry , Titrimetry/methods , Trypanosoma cruzi/chemistryABSTRACT
Up to 35% of pregnant women take psychotropic drugs at least once during gestation [Austin and Mitchell, 1998]. From concurrent animal and human evidence, it has been proposed that exposure to several psychoactive medications in utero or during lactation increases the risk for permanent brain disorders. Present preventive or therapy practices applied on humans for this type of long-lasting behavioral alterations are mainly based on empirical results. Here, we test an experimental approach designed to counteract a circling performance deficit that appears in Sprague-Dawley rats at puberty on exposure to the dopaminergic blocker haloperidol (HAL) during gestation [J.L. Brusés, J.M. Azcurra, The circling training: A behavioral paradigm for functional teratology testing, in: P.M. Conn (Ed.), Paradigms for the study of behavior, Acad. Press, New York, 1993, pp. 166-179. Method Neurosci. 14]. Gestational exposure to HAL (GD 5-18, 2.5 mg/kg/day ip) induced the expected circling activity decrease in the offspring at the fifth week of life. When prenatal exposure to HAL was continued through lactation (PD5-21, 1.5 mg/kg/day ip), rats otherwise showed a control-like circling performance. No difference was yet found between lactation-only, HAL-exposed pups and saline (SAL)-treated controls (n=8 each group). We further performed saturating (3H)-spiroperidol (SPI) binding assays on striatal P2 membrane fractions 2 months later. The dopamine-type D2-specific binding results suggested that above circling behavior findings could be partially explained by enduring HAL-induced neurochemical changes. The role of critical periods of sensitivity as transient windows for opportunistic therapies for behavioral teratology is discussed.
Subject(s)
Haloperidol , Prenatal Exposure Delayed Effects , Stereotyped Behavior/drug effects , Stereotypic Movement Disorder/drug therapy , Analysis of Variance , Animals , Animals, Newborn , Behavior, Animal/drug effects , Brain/drug effects , Dopamine Antagonists/pharmacokinetics , Dopamine Antagonists/therapeutic use , Dopamine Antagonists/toxicity , Female , Haloperidol/therapeutic use , Haloperidol/toxicity , Male , Pregnancy , Radioligand Assay/methods , Random Allocation , Rats , Rats, Sprague-Dawley , Spiperone/pharmacokinetics , Stereotypic Movement Disorder/chemically induced , Tritium/pharmacokineticsABSTRACT
2,4-Dichlorophenoxyacetic acid (2,4-D), a worldwide-used herbicide, has been associated with a range of adverse health effects on humans and different animal species. Although the mechanism of 2,4-D neurotoxicity remains unknown, we had previously reported changes in various neurotransmitter systems, such as serotonin (5-HT) and dopamine (DA), which were proposed to mediate some of the behavioral effects in rats. In the present work, we examined the impact of 2,4-D exposure on the ontogeny of dopaminergic D2-type receptors in prefrontal cortex (PFc), striatum (CPu), hippocampus (H) and cerebellum (Cer). Pregnant rats were orally exposed to 70 mg/kg/day of 2,4-D from gestation day (GD) 16 to postpartum day 23. After weaning, the pups were assigned to one of the two subgroups: T1 [fed with untreated diet until postnatal day, (PD) 90] and T2 [maintained with 2,4-D diet until PD 90]. Five to eight pups per age and sex were sacrificed at 6, 15, 30, 45 or 90 days of age for membrane receptor binding assays employing [3H]nemonapride. Subchronic 2,4-D exposure (T2 group) increased DA D2-type receptor around 40% in CPu. In addition, DA D2-type receptor levels also increased in PFc (15 and 30 days) and Cer (30 and 90 days). Sex-dependent differences in D2 receptors were observed with T2 female rats being more affected than T2 male rats. When the herbicide treatment was interrupted after weaning (T1 group), DA D2-type receptor density was apparently recovered and stabilized to control level. These findings suggest a reversible vulnerability of D2-type receptors to 2,4-D exposure. Regional increases of D2-type receptor density may explain certain behaviors reported early by us, such as catalepsy and right-turning preference in rats exposed to 2,4-D.
Subject(s)
2,4-Dichlorophenoxyacetic Acid/toxicity , Brain/drug effects , Herbicides/toxicity , Prenatal Exposure Delayed Effects , Receptors, Dopamine D2/metabolism , Age Factors , Analysis of Variance , Animals , Animals, Newborn , Brain/anatomy & histology , Brain/growth & development , Brain/metabolism , Female , Male , Pregnancy , Radioligand Assay/methods , Rats , Rats, Wistar , Sex FactorsABSTRACT
BACKGROUND: Studies in platelet of 5-HT uptake transporters have been performed using binding assay methodology designed for ligand-receptor interactions; however, uptake transporters present requirements that may question the validity of these particular binding assays. METHODS: To explore methodologic aspects that may be crucial to the validity of these assays, we studied the binding of [3H]-paroxetine to platelet membranes of healthy subjects under different conditions of time, temperature, and protein concentrations. RESULTS: A correlation between protein concentration in incubation media and percentage of specific binding of [3H]-paroxetine was found: the lower the protein concentrations (10 and 20 microg/mL) in incubation media, the lower the percentage of specific [3H]-paroxetine binding. Moreover, low specificity in [3H]-paroxetine binding affected Bmax values obtained in saturation binding experiments. CONCLUSIONS: The use of low protein concentrations could affect Bmax values in binding assays of 5-HT uptake transporters. This may induce confusing interpretation of data in clinical experiments that use human platelets to explore the participation of serotonin in depressed patients.
Subject(s)
Blood Platelets/metabolism , Carrier Proteins/metabolism , Paroxetine/metabolism , Radioligand Assay/methods , Selective Serotonin Reuptake Inhibitors/metabolism , Serotonin/metabolism , Adult , Humans , Middle Aged , Paroxetine/chemistry , Protein Binding , Reproducibility of Results , Serotonin Plasma Membrane Transport Proteins , Selective Serotonin Reuptake Inhibitors/chemistry , Temperature , Tritium/chemistry , Tritium/metabolismABSTRACT
A new radioligand-binding assay (RBA) is described for the detection of insulin/proinsulin-specific antibodies using 35S-labeled proinsulin produced by a cell-free reticulocyte extract. Direct use of the crude expression product in the RBA was not feasible because the protein failed to fold properly (or had incorrectly paired disulphide bridges) and purification was hindered by interfering by-products. A refolding protocol and a chromatographic procedure were devised that readily allowed production of purified and immunochemically competent 35S-labeled proinsulin. The new RBA was compared with the reference test, in which the tracer was standard 125I-insulin. The analysis included sera from 41 diabetic patients and 25 healthy controls. Twenty-six (63.4%) and 29 (70.7%) patients scored positive by RBA using 35S-PI and 125I-insulin, respectively. The methods showed a satisfactory correlation with r(2)=0.77 and a slope not significantly different from unity (m=1.16+/-0.10; 95% confidence interval). Since the nuclide used in the assay is 35S, the procedure is compatible with standard assays for GADA and IA-2A, and thus may permit combined assays for the major early markers of autoimmune diabetes.
Subject(s)
Antibodies/analysis , Insulin/immunology , Proinsulin/immunology , Radioligand Assay/methods , Diabetes Mellitus/immunology , Humans , Iodine Radioisotopes , Proinsulin/biosynthesis , Proinsulin/genetics , Protein Precursors/biosynthesis , Protein Precursors/genetics , Sulfur RadioisotopesABSTRACT
This study attempted to characterize pharmacologically the involvement of 5-HT(2A) receptors in 5-HT-induced contractile responses in human umbilical vein (HUV) rings employing functional and radioligand binding assays. In HUV rings, prazosin 1 micro M did not affect contractile responses elicited by 5-HT, ruling out the involvement of alpha(1)-adrenoceptors in contractile responses to 5-HT. 5-HT-induced contractions were competitively blocked by ketanserin, a 5-HT(2A)-selective antagonist. The apparent pA(2) value was 9.8 and the Schild slope significantly less than unity, suggesting that 5-HT-induced responses are mediated by a heterogeneous receptor population. Alpha-methyl-5-HT, a selective 5-HT(2) receptor agonist, induced contractions that were antagonized in a competitive manner by ketanserin. The slope regression was not significantly different from unity and the pA(2) value was 8.8. The selective 5-HT(2A) ligand spiperone produced a parallel rightward shift on 5-HT CRCs in HUV rings. The calculated pA(2) was 9.0, which is in accord for an interaction with the 5-HT(2A) receptor subtype. Alpha-methyl-5-HT CRCs were competitively blocked by spiperone treatment. The Schild analysis yielded a pA(2) of 9.1 with a slope not significantly different from unity. The 5-HT(2C/2A) antagonist mesulergine 10 nM did not affect 5-HT CRCs, suggesting that 5-HT(2C) receptors are not involved in 5-HT-elicited contractions. Higher concentrations of mesulergine showed a parallel rightward shift on 5-HT responses. The calculated pA(2) was 7.44, which suggests an interaction with the 5-HT(2A) receptor subtype. In addition, mesulergine competitively blocked alpha-methyl-5-HT CRCs. The Schild slope was not significantly different from unity and the p A(2) value was 7.98. The binding of [(3)H]ketanserin to HUV membranes was saturable and of high affinity. Ketanserin displayed a monophasic curve which was best fit with a single component of binding. Nonlinear least squares analysis of the binding curves revealed a high affinity K(d) of 0.30 nM and a B(max) of 134 fmol/mg protein. These findings provide strong pharmacological evidence of the involvement of 5-HT(2A) receptors in 5-HT-induced vasoconstriction in HUV. In addition, the contribution of another receptor population cannot be excluded. The results also suggest that this receptor population is neither an alpha(1)-adrenoceptor nor a 5-HT(2C) receptor subtype.
Subject(s)
Radioligand Assay/methods , Receptors, Serotonin/metabolism , Umbilical Veins/metabolism , Vasoconstriction/physiology , Dose-Response Relationship, Drug , Humans , In Vitro Techniques , Receptor, Serotonin, 5-HT2A , Serotonin/metabolism , Serotonin/pharmacology , Umbilical Veins/drug effects , Umbilical Veins/physiology , Vasoconstriction/drug effectsABSTRACT
Secure determination of the binding of 99mTc-radiopharmaceuticals to plasma (P) and blood cell (BC) constituents can help to understand the biodistribution of radiophamaceuticals. The reported precipitation studies of blood with radiopharmaceuticals have shown that the results can not be easily compared between studies. We decided to determine the "gold standard" concentration of trichloroacetic acid (TCA) to evaluate the binding to blood elements for several radiopharmaceuticals used in routine nuclear medicine. We have studied phytic (99mTc-PHY), diethylenetriaminepentaacetic (99mTc-DTPA), glucoheptonic (99mTc-GHA) and dimercaptosuccinic (99mTc-DMSA) acids. Blood was incubated with radiopharmaceuticals, centrifuged and P and BC separated. Samples of P and BC were also precipitated with TCA concentrations (20.0, 10.0, 5.0, 1.0, 0.5 and 0.1 percent) and soluble (SF) and insoluble fractions (IF) were isolated. The percent radioactivity (percent rad) in IF-P depends on TCA concentration. It varied from 36.4 to 65.0 (99mTc-PHY), from 17.9 to 32.0 (99mTc-DTPA), from 11.5 to 38.8 (99mTc-GHA) and from 52.8 to 66.2 (99mTc-DMSA). The results for the binding of 99mTc-PHY to IF-P show that there was no differences in the percent rad when TCA concentrations of 0.1 to 1.0 percent were used. For 99mTc-DTPA, 5.0 percent is the best TCA concentration. For 99mTc-GHA, low values of percent rad bound to IF-P is found with TCA concentrations of 0.1, 0.5 and 1.0. Interestingly, with 99mTc-DMSA, high values of bound radioactivity are not dependent on TCA concentrations (0.1 to 10.0). Radioactivity in IF-BC depends on TCA concentration and it varied for 99mTc-PHY (80.1 to 54.1) and for 99mTc-GHA (85.5 to 61.7). With 99mTc-DTPA and with 99mTc-DMSA the percent rad in IF-BC seems independent of TCA concentration. We suggest that the evaluation of the binding of the various 99mTc-radiopharmaceuticals to blood constituents, using only one TCA concentration, should be avoided.
Subject(s)
Blood Cells/drug effects , Radioligand Assay/methods , Technetium Compounds/metabolism , Animals , Blood Cells/metabolism , Male , Rats , Rats, Wistar , Trichloroacetic AcidABSTRACT
On type 1 newly diagnosed and on insulin treated diabetic patients, anti-insulin autoantibodies (IAA) and antibodies (IA) having the same specificity are respectively induced. Such immune response may be evaluated either by radiobinding assay (RBA) or enzyme-linked immunosorbent assay (ELISA). Both methodologies have been compared at previous International Workshops, which pointed out discrepancies in results. In this work, IAA/IA prevalence was assessed by displacement RBA and ELISA, in normal subjects, type 2 (treated with hypoglycaemic agents), insulin treated and newly diagnosed type 1 diabetic patients. Results showed a lack of RBA-ELISA agreement. An attempt was then made to determine whether such results were, at least in part, attributable to iodination site in Tyr-A14. For this purpose parallel RBA assays were carried out by using radiolabelled insulin at A14 and A19 Tyr residues. Control sera and samples from insulin treated and type 1 newly diagnosed diabetic patients were tested. Our results suggest that labelling position is not involved in artifactual binding of tracers, at least as a systematic phenomenon. In the majority of cases the variability in RBA-ELISA signal ratios are best explained in terms of differences in the basic principles operating in both methods instead of artifacts due to tracer preparation.
Subject(s)
Enzyme-Linked Immunosorbent Assay/methods , Insulin Antibodies/immunology , Insulin/immunology , Iodine Radioisotopes , Radioligand Assay/methods , Tyrosine , Adolescent , Adult , Aged , Autoantibodies/analysis , Autoantibodies/immunology , Binding Sites, Antibody/immunology , Child , Diabetes Mellitus, Type 1/immunology , Diabetes Mellitus, Type 2/immunology , Female , Humans , Insulin Antibodies/analysis , Male , Middle AgedABSTRACT
Non-linear regression and two-step linear fit methods were developed to determine the actual specific activity of 125I-ovine prolactin by radioreceptor self-displacement analysis. The experimental results obtained by the different methods are superposable. The non-linear regression method is considered to be the most adequate procedure to calculate the specific activity, but if its software is not available, the other described methods are also suitable.
Subject(s)
Radioligand Assay/methods , Animals , Female , Iodine Radioisotopes , Prolactin/analysis , Rats , Rats, Inbred Strains , Regression Analysis , SheepABSTRACT
The properties of type I and occupied and unoccupied type II cytosolic estrogen binding sites in the rat endometrium were analyzed on day five of pregnancy; the samples studied correspond to blastocyst receptive endometrium (implantation sites), nonreceptive endometrium and ovariectomized uterine horn endometrium, from the same pregnancy rats. The occupied binding site type II was analyzed by exchange assays. Dissociation constant obtained from experiments carried out at 4 or 25 degrees C are similar for each one of the binding site at the three different endometrium samples; the binding capacity (femtomoles/mg protein) from the sites type I and type II and the ratio between occupied (by endogenous estradiol) and unoccupied site type II, seems to be characteristic for each one of the three analyzed endometrium.
Subject(s)
Embryo Implantation/physiology , Endometrium/metabolism , Receptors, Estradiol/metabolism , Animals , Binding Sites/physiology , Cytosol/chemistry , Cytosol/metabolism , Endometrium/chemistry , Female , Pregnancy , Radioligand Assay/methods , Rats , Receptors, Estradiol/analysisABSTRACT
Se desarrolló un método radiorreceptor, relativamente rápido y de bajo costo, para determinar concentraciones de benzodiazepinas en fluidos biológicos. El método se basa en el hecho que la cantidad de [3H]-flunitrazepam incorporada específicamente, por fotomarcado, en receptores de membranas sinaptosomales, está relacionada cuantitativamente con la cantidad de benzodiazepina no radiactiva presente en el medio de incubación. Después del fotomarcado, las membranas fueron tratadas con ácido tricloroacético, y el sedimento obtenido fue lavado con acetona para eliminar el [3H]-flunitrazepam remanente, no unido. La preparación de receptor, constituida por membranas liofilizadas obtenidas a partir de corteza de cerebro bovino, fue estable durante seis meses por lo menos. El análisis estadístico de los gráficos logit-log de las curvas de desplazamiento con varias benzodiazepinas, mostró los siguientes valores de IC50: clonazepam, 1,6 nM; flunitrazepam, 3,8 nM; nitrazepam, 15,3 nM; diazepam, 43,2 nM; y clorodiazepóxido, 7,4 micronM, valores que se correlacionaron significativamente con los correspondientes valores determinados por otro método. Los valores de concentración correspondientes a benzodiazepinas no identificadas, extraídas de sangre, fueron expresados en equivalentes de diazepam. La sensibilidad para diazepam fue 3,3 nM, y los niveles de dosis entre 15 y 138 nM, mostraron valores de coeficiente de variación intra e inter ensayo, variando desde 3,4 a 12,2%, y desde 13 a 30,7%, respectivamente (AU)